The CAN-RELEASE study: Canadian real-life effectiveness of eptinezumab in migraine patients
Summary
This study aims to evaluate effectiveness in adult migraine patients who have initiated eptinezumab according to the local prescribing information, as well as the treatment patterns and health care resource utilisation (HCRU) in clinical practice.
Eligibility
Eligible ages: 18 to 100
Accepts healthy participants: Yes
Inclusion criteria:
• The patient has either Episodic Migraine (with 4 or more episodes per month), or Chronic Migraine.
• The patient is at least age 18.
• The patient is initiating eptinezumab according to the local prescribing information as part of routine care but has not yet received their first infusion.
• The patient is willing to bring their own device and download and use the provided application software.
Exclusion criteria:
• The patient has been administered investigational drugs within at least 3 months of enrollment.
• A time gap ˃ 2 months exists between patient informed consent and the date of first infusion, unless the patient has reconsented.
• The patient has previously been enrolled and dosed in any study with eptinezumab.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
CHAMP (Calgary Headache Assessment & Management Program) Research Office Outpatient Neurology, 5th Floor Clinic 5E South Health Campus 4448 Front St SE, Calgary, AB, Canada, T3M 1M4
Principal investigator:
Farnaz Amoozegar
Clinical trial:
No
REB-ID:
REB24-0483